跳至主要内容
临床试验/NCT06339541
NCT06339541招募中不适用

La Piattaforma ACC di Ricerca Preclinica Per l'Oncologia di Precisione

Fondazione del Piemonte per l'Oncologia1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2023年6月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
250
试验地点
1
主要终点
number of PDCM (patient derived cancer models)

研究概览

简要总结

The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.

详细描述

This is a retrospective and prospective observational study, focused on the implementation and validation of the application of PDCM, generated from tissue or cells of patients, including paediatric patients, with solid and haematological malignancies, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.

An up-to-date database of all PDCMs available at the participating italian hospitals will be generated and enriched with new models generated during the course of the project. The sharing of models and procedures between the different hospitals will facilitate their molecular and phenotypic characterisation, also in parallel with the tumours of origin, as well as their validation as tools for testing the efficacy of drugs for precision medicine. By establishing common workflows and standards and performing cross-validation experiments it is planned to build a network of reference centres as a resource for drug screening on 2D and 3D models.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Other

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.

排除标准

  • 未提供

结局指标

主要结局

number of PDCM (patient derived cancer models)

时间窗: 12 months

PDCM will be generated from tissues and cells

number of Whole Exome Sequencing (WES) e RNA-seq performed

时间窗: 12 months

WES and RNA seq will be performed on tissues and blood

次要结局

  • number of PDCM shared within the network(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Enzo Medico

Head of Oncogenomics

Fondazione del Piemonte per l'Oncologia

研究点 (1)

Loading locations...

相似试验